1. Scrip
  2. >>Business
  3. >>Strategy

Chinook Is Advancing Kidney Disease Goals With Surrogate Endpoints, Asian JV

 
• By Joseph Haas

Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.

Human Kidneys, 2d rendering
Chinook aims to offer precision kidney medicine on an international basis

Chinook Therapeutics, Inc. is developing a pair of drugs – an oral tablet and a monoclonal antibody – for IgA nephropathy, with potentially pivotal data expected for the oral drug in 2023. The Vancouver biotech has also garnered attention with an Asian joint venture that could provide entry to a region with a high prevalence of IgAN with limited capital and execution risk.

The company emerged in 2019 from the Versant Ventures incubator Inception Sciences, with a focus on precision medicine for chronic kidney disease and $65m in series A funding from Versant with participation in the round by Apple Tree and Samsara BioCapital. (Also see "Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines" - Scrip, 22 August, 2019.) Chinook then went public in June 2020 via a reverse merger with troubled Aduro Biotech, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.